Astellas says Phase 4 OPTION-VMS study shows VEOZAH improves menopause hot flashes at 12 weeks

• Astellas highlighted preliminary Phase 4 OPTION-VMS real-world findings for VEOZAH at the 2026 International Menopause Society congress.
• The analysis showed women treated with VEOZAH reported meaningful improvement in bothersome menopausal hot flashes by 12 weeks.
• Sleep outcomes also improved over the study period, including patient-reported sleep disturbance and wearable-measured sleep quality.
• No new safety signals emerged in the dataset, supporting continued uptake of the non-hormonal menopause therapy in routine practice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astellas Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610020800PR_NEWS_USPR_____CG62468) on October 02, 2026, and is solely responsible for the information contained therein.